JPS5941656B2 - Method for imparting anticoagulant properties to regenerated cellulose - Google Patents
Method for imparting anticoagulant properties to regenerated celluloseInfo
- Publication number
- JPS5941656B2 JPS5941656B2 JP56046287A JP4628781A JPS5941656B2 JP S5941656 B2 JPS5941656 B2 JP S5941656B2 JP 56046287 A JP56046287 A JP 56046287A JP 4628781 A JP4628781 A JP 4628781A JP S5941656 B2 JPS5941656 B2 JP S5941656B2
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- regenerated cellulose
- derivative
- reaction
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004627 regenerated cellulose Substances 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 24
- 230000002429 anti-coagulating effect Effects 0.000 title claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 57
- 229920000669 heparin Polymers 0.000 claims description 38
- 229960002897 heparin Drugs 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000002628 heparin derivative Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000178 monomer Substances 0.000 claims description 17
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims description 13
- 239000003505 polymerization initiator Substances 0.000 claims description 13
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
- 229920002554 vinyl polymer Polymers 0.000 claims description 11
- 229920000297 Rayon Polymers 0.000 claims description 10
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 claims description 8
- 239000002964 rayon Substances 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 229920000298 Cellophane Polymers 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910000831 Steel Inorganic materials 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 239000012510 hollow fiber Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 150000000703 Cerium Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- XEMZLVDIUVCKGL-UHFFFAOYSA-N hydrogen peroxide;sulfuric acid Chemical compound OO.OS(O)(=O)=O XEMZLVDIUVCKGL-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000009841 combustion method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- XFTALRAZSCGSKN-UHFFFAOYSA-M sodium;4-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=C(C=C)C=C1 XFTALRAZSCGSKN-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Graft Or Block Polymers (AREA)
- Macromonomer-Based Addition Polymer (AREA)
Description
【発明の詳細な説明】
本発明は再生セルロース又はその誘導体に抗血液凝固性
を賦与する方法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for imparting anticoagulant properties to regenerated cellulose or its derivatives.
このような再生セルロース系の材料は医用高分子材料と
して好適に用いられる。従来より再生セルロース又はそ
の誘導体にへパリンを固定して、抗血液凝固性の医用高
分子材料を得ることは知られている。Such regenerated cellulose-based materials are suitably used as medical polymer materials. It has been known to immobilize heparin on regenerated cellulose or its derivatives to obtain medical polymeric materials with anti-blood coagulation properties.
例えば酢酸セルロース膜をシアン化臭素で処理したのち
へパリンを固定する方法が、トランザクシヨンズアメリ
カンソサイエテイフオア アーテイフイシイアル イン
ターナル オーガンズの22巻第654頁(1976年
)に提案されており、四酢酸鉛または過ヨウ素酸、もし
くはその塩でセルロースを処理してへパリンを固定する
方法が、特開昭53−57288号公報に開示されてい
る。しかしながら、これ等従来のセルロースのヘパリン
化方法では、基体であるセルロースに直接へパリンを結
合し固定しているので、へパリンの固定量が少ないこと
、及びセルロースの処理に毒性の高い物質を使用するた
め、洗浄のコストが高くなること等の問題があり、実用
性に乏しいものであつた。For example, a method of fixing heparin after treating a cellulose acetate membrane with bromine cyanide is proposed in Transactions of the American Society for Artificial Internal Organs, Volume 22, Page 654 (1976). A method for fixing heparin by treating cellulose with lead tetraacetate, periodic acid, or a salt thereof is disclosed in JP-A-53-57288. However, in these conventional cellulose heparinization methods, heparin is directly bonded and immobilized to the cellulose substrate, so the amount of heparin immobilized is small, and highly toxic substances are used to treat cellulose. Therefore, there were problems such as increased cleaning costs, and the method was impractical.
本発明者等は、上記のような問題点につき種々検討の結
果、セルロース特に再生セルロースに、過酸化水素−F
e21系や、セリウム塩等の重合開始剤を用いて、グリ
シジルアクリレートまたはグリシジルメタアクリレート
をグラフト重合し、然る後にへパリン化する方法につい
て既に提案(特開昭57−18704)し、またグリシ
ジルアクリレート(以下GAと略す)またはグリシジル
メタアクリレート(以下GMAと略す)を重合禁止剤の
存在下にへパリンと反応させれば、重合性二重結合を持
ち、且つ殆んどヘパリンと変わらない抗血液凝固性を示
すヘパリン誘導体を提案した(特開昭56−14780
2)。As a result of various studies regarding the above-mentioned problems, the present inventors have found that hydrogen peroxide-F
We have already proposed a method of graft polymerizing glycidyl acrylate or glycidyl methacrylate using a polymerization initiator such as e21 system or cerium salt, and then converting it into heparin (Japanese Patent Application Laid-open No. 18704/1983). (hereinafter abbreviated as GA) or glycidyl methacrylate (hereinafter abbreviated as GMA) is reacted with heparin in the presence of a polymerization inhibitor. He proposed a heparin derivative that exhibits coagulability (Japanese Patent Application Laid-Open No. 14780-1980)
2).
これ等の知見から今回更にヘパリンとGAまたはGMA
を結合して得られたヘパリン誘導体と1種類以上の重合
性ビニルモノマー、及び再生セルロース(水酸基を持つ
再生セルロース誘導体を含む)を、再生セルロースへの
グラフト重合開始剤を用いて反応させることにより、再
生セルロースにヘパリンを結合した極めて抗凝血性の高
い材材が得られることが解り、本発明を完成するに到つ
た。即ち本発明は、ヘパリンにGAやGMAのような重
合性二重結合を持つエポキシドモノマ一を反応させるこ
とによつて得られる重合性二重結合を持つヘパリン誘導
体と、重合性二重結合を持つ1種類または2種類以上の
ビニルモノマーとを重合開始剤の存在下水系溶媒中で、
再生セルロースまたは実質的に水酸基を有する再生セル
ロース誘導体にグラフト共爪合して、再生セルロースま
たはその誘導体に抗血液凝固性を賦与する方法を提供す
るものである。本発明に用いられる再生セルロースの例
としては、銅アンモニアレーヨン、ビスコースレーヨン
、セロフアン等がある。再生セルロース誘導体としては
、セリウム塩や、過酸化水素一鉄塩系の重合開始剤でグ
ラフト重合可能な、実質的に水酸基を有するものであれ
ばよく、このようなものの代表的な例は、酢酸セルロー
ス、カルボキシメチルセルロース、カルボキシエチルセ
ルロース、メチルセルロース、ヒドロキシエチルセルロ
ース、セルロースアセテートプロピオネート、セルロー
スアセテートブチレート、シアノエチルセルロース、ニ
トロセルロース等があるが、このうち医療用成形体とし
て特に軍要なものは酢酸セルロースである。本発明に用
いられるヘパリン誘導体は例えば特開昭56−1478
02明細書に示したように、GAまたはGMAとヘヘパ
リンをラジカル重合禁止剤の存在下に水系溶液中で反応
させて得られたものであり、その物理的・化学的性質、
及び生物学的活性はヘパリンとほとんど変らないもので
ある。Based on these findings, we have further added heparin and GA or GMA.
By reacting the heparin derivative obtained by bonding with one or more types of polymerizable vinyl monomer and regenerated cellulose (including regenerated cellulose derivatives having a hydroxyl group) using a graft polymerization initiator to the regenerated cellulose, It was found that a material with extremely high anticoagulant properties can be obtained by bonding heparin to regenerated cellulose, and the present invention was completed. That is, the present invention provides a heparin derivative having a polymerizable double bond obtained by reacting heparin with an epoxide monomer having a polymerizable double bond such as GA or GMA, and one or more vinyl monomers in an aqueous solvent in the presence of a polymerization initiator,
The present invention provides a method for imparting anti-blood coagulability to regenerated cellulose or a derivative thereof by grafting it onto regenerated cellulose or a regenerated cellulose derivative having substantially hydroxyl groups. Examples of regenerated cellulose used in the present invention include cuprammonium rayon, viscose rayon, and cellophane. The regenerated cellulose derivative may be one that substantially has a hydroxyl group and can be graft-polymerized with a cerium salt or monoferrous hydrogen peroxide based polymerization initiator.A typical example of such a derivative is acetic acid. There are cellulose, carboxymethylcellulose, carboxyethylcellulose, methylcellulose, hydroxyethylcellulose, cellulose acetate propionate, cellulose acetate butyrate, cyanoethylcellulose, nitrocellulose, etc. Among these, cellulose acetate is particularly important as a medical molded product. be. The heparin derivatives used in the present invention are disclosed in, for example, JP-A-56-1478.
As shown in the specification, it is obtained by reacting GA or GMA and heheparin in an aqueous solution in the presence of a radical polymerization inhibitor, and its physical and chemical properties,
And its biological activity is almost the same as that of heparin.
本発明におけるヘパリンの結合量を示すヘパリン化率(
その定義は実施例1に示されている。Heparinization rate (which indicates the amount of heparin binding in the present invention)
Its definition is shown in Example 1.
)は反応条件、反応対象物の形状等によつて変わるが、
例えば厚さ18μm1直径50m77!のキユプアンモ
ニウムレーヨンフイルムを用いた場合で約5%以上にな
る。本発明に用いられる爪合性ビニルモノマーとしては
、硝酸第2セリウムアンモニウム、過酸化水素一硫酸鉄
系等の重合開始剤の存在下、水系溶媒中で再生セルロー
ス、またはその誘導体にグラフト歌合可能なものであれ
ば特に制限はない。) varies depending on the reaction conditions, the shape of the reaction target, etc.
For example, thickness 18 μm 1 diameter 50 m 77! When a Kyupammonium rayon film is used, it becomes about 5% or more. The vinyl monomer used in the present invention can be grafted onto regenerated cellulose or its derivatives in an aqueous solvent in the presence of a polymerization initiator such as ceric ammonium nitrate or hydrogen peroxide monosulfate. There are no particular restrictions as long as it is.
この重合性ビニルモノマーは再生セルロースまたはその
誘導体とGAまたはGMAのヘパリン誘導体とを結合す
る働きがある。従つて親水性であることがヘパリン誘導
体及び再生セルロース等との反応において望ましい。こ
のようなビニルモノマーの例としては、アクリルアミド
、アクリル酸及びその塩、2−ヒドロキシエチルメタア
タリレート、アクリロニトリル、N−ビニルピロリドン
、P−スチレンスルホン酸ソーダ、アクリル酸メチル、
メタアクリル酸メチル、酢酸ビニル、アクリルスルホン
酸ソーダ、GA,GMAl等がある。This polymerizable vinyl monomer has the function of binding regenerated cellulose or its derivative and the heparin derivative of GA or GMA. Therefore, hydrophilic properties are desirable in reactions with heparin derivatives, regenerated cellulose, and the like. Examples of such vinyl monomers include acrylamide, acrylic acid and its salts, 2-hydroxyethyl methacrylate, acrylonitrile, N-vinylpyrrolidone, sodium p-styrenesulfonate, methyl acrylate,
Examples include methyl methacrylate, vinyl acetate, sodium acrylic sulfonate, GA, and GMAl.
本発明の方法において、グラフト共重合反応における好
ましい水系溶媒は水である。In the method of the present invention, the preferred aqueous solvent in the graft copolymerization reaction is water.
しかしモノマーの溶解か不充分なときは、ヘパリン誘導
体が溶解する範囲で有機溶剤を水に加えることができる
。例えばアセトンと水の比を1:2(容積比)、ホルム
アミドと水の比を1:9(容積比)程度迄は有機溶剤と
の混合溶媒とすることがで来る。その他N,N−ジメチ
ルアセトアミド、N,N′−ジメチルホルムアミド、メ
チルエチルケトン、ジオキサン等の親水性を持つた有機
溶剤も、水との混合溶媒として使用可能である。これ等
の混合溶媒を用いれば親水性のないスチレンの如きモノ
マーでも、少量ならばグラフト共重合が可能である。本
発明に用いる重合開始剤の例としては、硝酸第2セリウ
ムアンモニウムに代表されるセリウム塩系開始剤、過酸
化水素一硫酸第1鉄塩に代表される過酸化水素一金属塩
系開始剤等がある。本発明に用いられる再生セルロース
またはその誘導体は、平膜、中空糸、繊維のような成形
されたものを使用することが望ましい。その理由は未成
形のものの場合、反応溶媒が極めて限度され、ヘパリン
誘導体の爵解を可能にするものが極めて見出し難いこと
、また仮りにヘパリン誘導体の溶解が可能であつてもヘ
パリンの活性が失なわれる可能性が大きいこと、更には
表面だけにヘパリンが固定されれば十分な場合でも、未
成形品を用いる場合は内部まで一様に固定され極めて不
経済であること等である。例えば、銅アンモニアレーヨ
ンの溶媒である銅アンモニア液に、GAまたはGMAの
ヘパリン誘導体は溶解するけれども、その強アルカリ性
によつてヘパリン活性はその殆んどが失なわれ、抗凝血
性も失なわれる可能性が大きい。本発明の好ましい実施
態様は、前記水系溶媒中に重合性二重結合をもつ1種類
以上のビニルモノマーと、GAまたはGMAを結合した
ヘパリン誘導体とを、溶解する範囲で適当量加え、これ
に再生セルロースまたはその誘導体の成形物を加え、更
に重合開始剤と必要に応じて硝酸等の酸を入れ、完全に
窒素置換を行なつて反応させる。However, if the monomer is insufficiently dissolved, an organic solvent can be added to the water to the extent that the heparin derivative is dissolved. For example, a mixed solvent with an organic solvent can be used up to a ratio of acetone to water of about 1:2 (volume ratio) and a ratio of formamide to water of about 1:9 (volume ratio). Other hydrophilic organic solvents such as N,N-dimethylacetamide, N,N'-dimethylformamide, methyl ethyl ketone, and dioxane can also be used as a mixed solvent with water. If these mixed solvents are used, even monomers such as styrene, which are not hydrophilic, can be graft copolymerized in small amounts. Examples of the polymerization initiator used in the present invention include cerium salt-based initiators represented by ceric ammonium nitrate, hydrogen peroxide monometallic salt-based initiators represented by ferrous hydrogen peroxide monosulfate, etc. There is. The regenerated cellulose or its derivative used in the present invention is preferably shaped into a flat membrane, hollow fiber, or fiber. The reason for this is that in the case of an unformed product, the reaction solvent is extremely limited, and it is extremely difficult to find a solvent that can dissolve the heparin derivative, and even if it is possible to dissolve the heparin derivative, the heparin activity will be lost. Furthermore, even if it is sufficient to fix heparin only on the surface, if an unmolded product is used, it will be fixed uniformly to the inside, which is extremely uneconomical. For example, although heparin derivatives such as GA or GMA are dissolved in cupric ammonium solution, which is the solvent for cupric ammonium rayon, most of the heparin activity and anticoagulant properties are lost due to its strong alkalinity. There is a big possibility. In a preferred embodiment of the present invention, an appropriate amount of one or more vinyl monomers having a polymerizable double bond and a heparin derivative bonded with GA or GMA are added to the aqueous solvent within a range in which they are dissolved, and then regenerated. A molded product of cellulose or a derivative thereof is added, a polymerization initiator and, if necessary, an acid such as nitric acid are added, and the mixture is completely replaced with nitrogen to react.
水系溶媒は予じめ凍結点以上90℃以下、望ましくは凍
結点以上60℃以下に保つておくのがよい。一般的につ
いて低温程ヘパリン結合量は増加し、またその場合のヘ
パリン活性も高いが反応時間がかかる傾向にあり、反面
温度が高いと反応速度は速いがあまり速すぎるとコント
ロールが難かしくなり、またヘパリンの分解も増加して
結合ヘパリンの活性が低下するなどの影響がある。反応
に際しての仕込み比率は、溶媒の20′C付近の1重量
部当りを基準にすると次のようになる。The aqueous solvent is preferably kept in advance at a temperature above the freezing point and below 90°C, preferably above the freezing point and below 60°C. Generally speaking, the lower the temperature, the more heparin binds, and the higher the heparin activity, the longer the reaction time will be.On the other hand, if the temperature is high, the reaction rate will be fast, but if it is too fast, it will be difficult to control. Heparin degradation also increases and the activity of bound heparin decreases. The charging ratio for the reaction is as follows, based on 1 part by weight of the solvent at around 20'C.
再生セルロースの量は、下限は任意であるが上限は経験
的に0.06重量部位まで可能である。ヘパリン誘導体
の量は0.001〜0.5重量部、好ましくは0.05
〜0.3重量部である。この範囲の下限は反応速度、反
応量等からきまり、上限は溶解性、粘性から制限される
。重量性ビニルモノマーの量は、0.0001〜0.1
重量部の間であり、主としてヘパリン化率を最大とする
ような範囲に実験によつて決められる。The lower limit of the amount of regenerated cellulose is arbitrary, but the upper limit can be up to 0.06 parts by weight based on experience. The amount of heparin derivative is 0.001 to 0.5 parts by weight, preferably 0.05 parts by weight.
~0.3 parts by weight. The lower limit of this range is determined by reaction rate, reaction amount, etc., and the upper limit is determined by solubility and viscosity. The amount of heavy vinyl monomer is 0.0001 to 0.1
The amount is between parts by weight, and is determined by experiment, mainly within a range that maximizes the heparinization rate.
重合開始剤はセリウム塩系、過酸化水素系ともに、でき
るだけ小量の方が、反応後の残留重合開始剤の洗浄が容
易であり、かつ、同じグラフト率ではヘパリン化率が高
くなる傾向にあるため有利である。しかしあまり少なす
ぎるとグラフト率が小さくなりすぎる。望ましい量は過
酸化水素、セリウム塩ともに溶媒11当り0.01〜1
0mm011好ましくは0.1〜2mm01程度である
。また、過酸化水素に対する鉄塩、硝酸第2セリウムア
ンモニウムに対する硝酸の量は夫々およそ%〜5倍の範
囲がよい。再生セルロースまたはその誘導体が中空糸で
あつて、その内面にのみヘパリン誘導体を結合する場合
には、完全密閉可能な中空糸型人工腎臓と同様の形態の
モジユールを作り、これに同じく密閉可能なフラスコか
ら、ヘパリン誘導体、ビニルモノマー、重合開始剤、及
び少量の酸を加えた水溶液を導入循環させることにより
反応を行うことができる。For both cerium salt-based and hydrogen peroxide-based polymerization initiators, it is easier to wash away residual polymerization initiators after the reaction if the amount is as small as possible, and the heparinization rate tends to be higher at the same grafting rate. Therefore, it is advantageous. However, if it is too small, the grafting rate will be too small. The desirable amounts for both hydrogen peroxide and cerium salt are 0.01 to 1 per 11 parts of the solvent.
0 mm011, preferably about 0.1 to 2 mm01. Further, the amount of iron salt relative to hydrogen peroxide and the amount of nitric acid relative to ceric ammonium nitrate are preferably in the range of about % to 5 times, respectively. If regenerated cellulose or its derivatives are hollow fibers and a heparin derivative is bonded only to the inner surface, a module with a form similar to a completely sealable hollow fiber artificial kidney is made, and a flask that is also sealable is prepared. The reaction can be carried out by introducing and circulating an aqueous solution containing a heparin derivative, a vinyl monomer, a polymerization initiator, and a small amount of acid.
勿論モジユール、フラスコ及び反応液を含めた全体の系
を完全に窒素置換して反応を行うことが好ましい。反応
温度は上記の範囲であれば、ヘパリン活性保持及び反応
速度のコントロールの2つの面から有利であり、また反
応時間は温度、開始剤濃度、モノマー濃度、モノマー種
類及びヘパリン誘導体に結合しているGAまたは、GM
Aの量などによつて異なるが、10分〜10時間程度の
範囲で行われる。反応したヘパリン誘導体及びモノマー
の量は、反応前後の再生セルロースまたはその誘導体の
重量差及び、ヘノマリンの比濁法、イオウ燃焼法等によ
るイオウ分測定からのヘパリン量推定等から精度よく推
定値を得ることが出来る。ヘパリンの結合を定性的にみ
るにはアズールAにより染色して、藍紫色へのメタクロ
マジ一を観察すればよい。再生セルロースまたはその誘
導体へ結合したヘパリンの効果は、犬の全血を用いたリ
ンドホルムセルによる凝血時間測定値で判断できる。こ
の場合の測定法は、リンドホルムテストと呼ばれている
方法で行うことができ、その概要は次の通りである。先
づ、乾燥重量で約1グラムのヘノマリンを結合したフイ
ルムを、25重量%の食塩水500meに10時間浸漬
し、食塩水をとりかえてこの操作を2回くり返し、イオ
ン結合及びこれに類する離反しやすいヘパリンを除去す
る。このフイルムを大量の生理食塩水で洗つた後、ガラ
ス板上にのせて、その上から中央に20關ψの孔をあけ
た厚み5mmのシリコンガスケツトで押さえ、更に同一
径の孔を有するガラス板で上から押さえて締めつけるこ
とによりリンドホルムセルを組立てる。犬の頚静脈から
最所の0.5TLeを流し捨てた後の全血を5me程度
採血して、直ちに1検体当り正確に0.5rneをフイ
ルム上にまんべんなく広げ、最初の20分間は5分毎に
、20分以後は2分毎に452傾けて血液が凝固して動
かなくなる迄の時間を測定する。犬3頭について夫々1
回測定し、3頭の犬の血液凝固時間の平均値で示す。本
発明によつて得られる抗凝血性再生セルロースまたはそ
の誘導体は、不純物として少量の重合開始剤及びビニル
モノマーを含む場合もあるが、それらは比較的容易に水
洗によつて除くことが出来る。Of course, it is preferable to carry out the reaction by completely purging the entire system including the module, flask, and reaction solution with nitrogen. If the reaction temperature is within the above range, it is advantageous from the two aspects of maintaining heparin activity and controlling the reaction rate, and the reaction time is linked to the temperature, initiator concentration, monomer concentration, monomer type, and heparin derivative. GA or GM
Although it varies depending on the amount of A, etc., it is carried out for about 10 minutes to about 10 hours. The amounts of reacted heparin derivatives and monomers can be accurately estimated from the weight difference between the regenerated cellulose or its derivatives before and after the reaction, and from estimating the amount of heparin from measuring the sulfur content by the henomarin nephelometric method, sulfur combustion method, etc. I can do it. To qualitatively examine the binding of heparin, it is sufficient to stain with Azure A and observe the metachromatic coloration to deep blue. The effectiveness of heparin bound to regenerated cellulose or its derivatives can be determined by clotting time measurements using a Lindform cell method using canine whole blood. The measurement method in this case can be carried out by a method called Lindholm test, the outline of which is as follows. First, a film bound with about 1 gram of henomarin by dry weight was immersed in 500ml of 25% by weight saline for 10 hours, and the saline was replaced and this operation was repeated twice to eliminate ionic bonds and similar dissociation. Easy to remove heparin. After washing this film with a large amount of physiological saline, place it on a glass plate, press it with a 5 mm thick silicone gasket with a hole of 20 ψ in the center, and then cover it with a glass plate with a hole of the same diameter. Assemble the Lindholm cell by pressing down and tightening it with a board. After discarding the most 0.5 TLe from the dog's jugular vein, collect about 5 me of whole blood and immediately spread exactly 0.5 TLe per sample evenly on the film, every 5 minutes for the first 20 minutes. After 20 minutes, tilt the tube 452 every 2 minutes to measure the time until the blood coagulates and stops moving. 1 each for 3 dogs
The blood clotting time was measured twice and is shown as the average value of the blood clotting time of 3 dogs. The anticoagulant regenerated cellulose or its derivatives obtained by the present invention may contain small amounts of polymerization initiators and vinyl monomers as impurities, but these can be relatively easily removed by washing with water.
またビニルモノマーは比較的安価なものが使用できるの
でコストが安く実用性が高い。更に再生セルロースまた
はその誘導体に直接ヘパリンを結合させる方法に比較し
て、本発明のものはグラフト重合体の枝分子の所々にヘ
パリンが結合した形態になつていると推定される。そし
てヘパリンが大量に且つ、極めて効率良く固定されてい
るため、より良好な抗凝血性を示す。本発明によつて得
られた再生セルロースまたはその誘導体は、適当な反応
条件を選べば平膜または中空糸として、あるいは透析や
濾適用の膜として応用可能であり、更に繊維の形態で作
れば手術用縫合糸としても使用可能である。次に実施例
により、本発明を更に具体的に説明する。Furthermore, since relatively inexpensive vinyl monomers can be used, the cost is low and the practicality is high. Furthermore, compared to the method of directly bonding heparin to regenerated cellulose or its derivatives, the method of the present invention is presumed to have heparin bonded to some of the branch molecules of the graft polymer. Since heparin is immobilized in large quantities and extremely efficiently, it exhibits better anticoagulability. The regenerated cellulose or its derivatives obtained by the present invention can be applied as a flat membrane or hollow fiber, or as a membrane for dialysis or filtration, if appropriate reaction conditions are selected, and if it is made in the form of fibers, it can be used in surgical procedures. It can also be used as a surgical suture. Next, the present invention will be explained in more detail with reference to Examples.
実施例 1
ヘパリンナトリウム(半丼化学薬品、1501U/M7
)10グラムを蒸留水に溶解し、10重量%溶液とする
。Example 1 Heparin sodium (Handon Chemicals, 1501U/M7
) Dissolve 10 grams in distilled water to make a 10% by weight solution.
これに重合禁止剤としてP−メトキシフエノール0.1
(f)を加えたGMA577ll!を加え、攪拌下50
′Cに加熱し16時間反応させる。反応後、反応液をロ
ータリーエバポレーターで濃縮し、メタノール11中に
撹拌下投人し白色粉末沈澱を得る。得られた沈澱を回収
し、メタノールで十分洗浄したのち再び少量の水に溶解
させ、同じ操作を行い沈澱を回収し、真空乾燥器で恒量
に達するまで乾燥した。得られた物質は、出発物質のヘ
パリンと大略同一の物理的性質を有し白色で吸湿性の粉
末であり、水に溶け、メタノール、アセトン等の有機溶
剤に不溶性である。この生成物を水に溶かし、ゲルパー
ミエーシヨンクロマトグラフを測定した所、ほぼ完全に
出発物質と変わらないクロマトグラフを与え、ヘパリン
に結合したGMAの二重結合は重合を起していないこと
が解つた。また、赤外スペタトル及びNMRスペクトル
からもGMAとヘパリンが結合していることが確かめら
れた。赤外スペクトルから求めた結合GMA量は、ヘパ
リン19に対して約0.2mm01であつた。このヘパ
リン誘導体を〔1〕とし、次の反応に用いた。500m
eの4つロフラスコに厚さ18μm1直径50mmの円
形の銅アンモニアレーヨンフイルム1,0g(約30枚
)と共に下記に示す配合で仕込み、密閉して減圧にする
方法を3回繰返して窒素置換を行つた後、反応を行なつ
た。Add to this 0.1 P-methoxyphenol as a polymerization inhibitor.
GMA577ll with (f) added! and stirred for 50 minutes.
'C and react for 16 hours. After the reaction, the reaction solution was concentrated using a rotary evaporator and poured into 11 methanol with stirring to obtain a white powder precipitate. The obtained precipitate was collected, thoroughly washed with methanol, dissolved again in a small amount of water, the same operation was performed, the precipitate was collected, and it was dried in a vacuum dryer until it reached a constant weight. The resulting material is a white, hygroscopic powder with roughly the same physical properties as the starting material heparin, soluble in water and insoluble in organic solvents such as methanol and acetone. When this product was dissolved in water and gel permeation chromatography was performed, it showed a chromatography that was almost completely the same as that of the starting material, indicating that the double bonds of GMA bound to heparin were not polymerized. I solved it. Furthermore, it was confirmed from the infrared spectrum and NMR spectra that GMA and heparin were bonded. The amount of bound GMA determined from the infrared spectrum was about 0.2 mm01 for heparin 19. This heparin derivative was designated as [1] and used in the next reaction. 500m
Fill the following four flasks with 1.0 g (approximately 30 sheets) of circular copper ammonia rayon film 18 μm thick and 50 mm in diameter using the composition shown below, and repeat the method of sealing and reducing the pressure three times to purge with nitrogen. After that, the reaction was carried out.
反応温度は30℃であつた。銅アンモニアレーヨン(1
8/111176約30枚)1.0g50m77!ψ窒
素置換の後、マグネチツクスターラ一で攪拌し、1時間
後に反応を停止して、大量の水中に銅アンモニアレーヨ
ンフイルムを投入して洗浄し、グラフト率、ヘパリン化
率、リンドホルムテスト等により、未反応のフイルムと
比較した。The reaction temperature was 30°C. Copper ammonia rayon (1
8/111176 approx. 30 pieces) 1.0g50m77! After ψ nitrogen substitution, the reaction was stopped with a magnetic stirrer, and the reaction was stopped after 1 hour. A copper ammonia rayon film was poured into a large amount of water and washed, and the grafting rate, heparinization rate, Lindholm test, etc. , compared with unreacted film.
グラフト率、ヘパリン化率は、次の式の定義によつた。
反応によつて結合したヘパリン量の測定は、反応物の硫
酸根を酸加水分解によつてとり出し、これに塩化バリウ
ムのゼラチン溶液を加え、比濁法により測定した硫酸根
の量から推定したものである。次に測定の結果を示す。
これ等の結果から、8.1×10−5(g眉)のヘパリ
ンが結合しており、著しい凝血時間延長をもたらすこと
が解る。The grafting rate and heparinization rate were defined by the following formulas.
The amount of heparin bound by the reaction was measured by extracting the sulfate radicals of the reactant by acid hydrolysis, adding a gelatin solution of barium chloride to this, and estimating the amount of sulfate radicals measured by turbidimetry. It is something. Next, the measurement results are shown.
These results show that 8.1 x 10-5 (g) of heparin is bound, resulting in a significant prolongation of the coagulation time.
このフイルムの透水速度を圧力差50m77!/Hgで
測定した所、未反応フイルムが37℃で3。The water permeability rate of this film has a pressure difference of 50m77! /Hg, the unreacted film was 3 at 37°C.
2(Me/Hrm2・MmHg)であつたのに比し1.
95(d/Hrm2・M77!Hg)であり、透析型及
び、濾過型人工腎臓膜として十分応用可能性が高い。2 (Me/Hrm2・MmHg), compared to 1.
95 (d/Hrm2·M77!Hg), and has high applicability as a dialysis type and filtration type artificial kidney membrane.
実施例 2
ヘパリンナトリウム5gを蒸留水に溶かし5%溶液とし
、これにP−メトキシフエノール0.5%を含むGA2
meを加え40゜Cで24時間反応させた。Example 2 5g of heparin sodium was dissolved in distilled water to make a 5% solution, and GA2 containing 0.5% of P-methoxyphenol was added to the solution.
Me was added and reacted at 40°C for 24 hours.
反応生成物を実施例1のヘパリン誘導体〔1〕と同様の
方法で回収精製した。この生成物は赤外スペクトルから
二重結合を有するGAが結合したヘパリン誘導体である
ことが確認された。この生成物をヘパリン誘導体〔〕と
し、次の配合で40℃に保つた恒温槽の中に据えつけて
、500dの4つロフラスコに仕込んだ。〔18μm厚
、50mゆ約30枚〕
以上を仕込んで窒素置換を行い、実施例1と同様の方法
で反応及び洗浄した。The reaction product was recovered and purified in the same manner as for heparin derivative [1] in Example 1. This product was confirmed from an infrared spectrum to be a heparin derivative bound to GA having a double bond. This product was made into a heparin derivative [], and the following formulation was placed in a constant temperature bath kept at 40°C, and charged into a 500 d four-hole flask. [Approximately 30 sheets, 18 μm thick, 50 m long] The above materials were charged, replaced with nitrogen, and reacted and washed in the same manner as in Example 1.
反応温度は25゜Cで、反応時間は1.5時間であつた
。実施例1と同じようにテストを行い次の結果を得た。
以上の結果から、本発明の方法で充分にヘパリンが結合
し抗凝血性が高いフイルムが得られたことが解る。The reaction temperature was 25°C and the reaction time was 1.5 hours. A test was conducted in the same manner as in Example 1, and the following results were obtained.
The above results demonstrate that the method of the present invention was able to sufficiently bind heparin and produce a film with high anticoagulant properties.
このフイルムを圧力50mnHgで透水速度の測定をし
た所、2.25((4−1rm2・MmHg)であつた
。未反応フイルムは3.2(MlAlrm2・MmHg
)であるから、人工腎臓用の透析膜としての応用可能性
が十分大きいことが解つた。実施例 3
銅アンモニアレーヨン中空糸(旭化成製品、内径200
μm1外径226μm)を用い、ポツテイング剤として
ウレタンを用いて中空糸型人工腎臓モジユールの形に組
立てた(透析液出入口間距離9.0?、中空糸5000
本、透析器内径2,6CTL)斯くして作つた2本のモ
ジユールのそれぞれの透析液出入口の一方の口を一諸に
窒素源に接続し、他方の口を各々ピンチコツク付ゴム管
につなぎ、ピンチコツクを閉じ密閉した。When the water permeation rate of this film was measured at a pressure of 50 mnHg, it was 2.25 ((4-1rm2・MmHg).The unreacted film was 3.2 (MlAlrm2・MmHg).
), it was found that the possibility of application as a dialysis membrane for artificial kidneys is large enough. Example 3 Copper ammonia rayon hollow fiber (Asahi Kasei product, inner diameter 200
μm1 (outer diameter 226 μm), and using urethane as a potting agent, it was assembled into a hollow fiber type artificial kidney module (distance between dialysate inlet and outlet 9.0?, hollow fiber 5000 mm).
Dialyzer inner diameter: 2.6CTL) Connect one end of the dialysate inlet/outlet of each of the two modules thus made to a nitrogen source, and connect the other end to a rubber tube with a pinch stopper. The pinch bottle was closed and sealed.
また2本のモジユールの血液出入口のそれぞれの一方を
一諸にして21の四つロフラスコの一つの開口部にチユ
ーブでつなぎ、他方はそれぞれローラーポンプを介して
チユーブにて四つロフラスコの他の開口部の一つの合流
させるようにつないだ。四つロフラスコの他の2つの開
口部は一方を温度計挿入口として用い、他方をフラスコ
及び回路の窒素置換用のため窒素源につないだ。このよ
うな回路構成により、フラスコ内の反応液がモジユール
内の中空繊維を通つて再びフラスコ内に戻るようにした
。モジユール内部での反応液の通過速度は10me/M
L.になるように調整した。反応液を四つロフラスコ内
に次の配合で仕込み、直ちにモジユール内も含めて減圧
一窒素導入による常圧回復のサイクル操作を3回繰り返
して窒素置換を行い、次に40℃に保つてローラーポン
プで循環し、40分間反応した後、モジユールを取り出
して大量の蒸留水で洗浄した。Also, one of the blood inlets and outlets of the two modules is connected to one opening of the 21 four-loop flasks with a tube, and the other one is connected to the other opening of the four-loop flask via a roller pump, respectively. Connect them so that one of the parts joins. The other two openings in the four-ring flask were connected to a nitrogen source for nitrogen purging of the flask and circuit, one used as a thermometer insertion port and the other for nitrogen purging of the flask and circuit. With this circuit configuration, the reaction solution in the flask was allowed to return to the flask through the hollow fibers in the module. The passage speed of the reaction liquid inside the module is 10me/M
L. I adjusted it so that The reaction solution was charged in four Lof flasks according to the following composition, and immediately the cycle of reducing pressure and introducing nitrogen into the module was repeated three times to purge with nitrogen. Next, the temperature was maintained at 40°C and the roller pump was heated. After reacting for 40 minutes, the module was taken out and washed with a large amount of distilled water.
洗浄したモジユールの1本を破壊して中空糸を取り出し
、これを25%食塩水500me中に10時間浸漬する
操作を2回、食塩水をとりかえて行い、更に、生理食塩
水で良く洗浄した後、ビークル犬の頚静脈からダブルシ
リンジ法で採血した直後の血液を入れて両端を閉じ、3
7℃のインキベータ中にポリエチレン袋で密閉して放置
した。One of the washed modules was destroyed, the hollow fiber was taken out, and the fiber was immersed in 500 me of 25% saline twice for 10 hours, changing the saline twice, and then thoroughly washed with physiological saline. , Put the blood that has just been collected from the jugular vein of the vehicle dog using the double syringe method, close both ends, and
It was left sealed in a polyethylene bag in an incubator at 7°C.
同時に未反応の中空糸も同じ操作で血液を入れ比較試験
とした。ヘパリンを結合した中空糸では240分後も凝
血していなかつたのに対し、未反応の中空糸では60分
後に凝血していた。また膜に対して、400mmHgで
透水速度をもう一つのモジユールについて測定した所、
2.50(Me/Hr.m2.mTLHg)であつた。At the same time, blood was added to the unreacted hollow fiber using the same procedure for a comparative test. The hollow fibers bound with heparin did not cause blood clots even after 240 minutes, whereas the unreacted hollow fibers showed blood clots after 60 minutes. In addition, when the water permeation rate was measured for another module at 400 mmHg for the membrane,
It was 2.50 (Me/Hr.m2.mTLHg).
Claims (1)
ルメタアクリレートを結合して得られたヘパリン誘導体
と、1種類以上の重合性ビニルモノマー及び、再生セル
ロースまたはその誘導体を重合開始剤の存在下に水係溶
媒中で反応させることを特徴とする再生セルロースに抗
血液凝固性を賦与する方法。 2 重合開始剤が過酸化水素−Fe^2^+系または硝
酸第2セリウムアンモニウムである特許請求の範囲第1
項記載の方法。 3 水系溶媒が水である特許請求の範囲第1項記載の方
法。 4 反応温度が凍結点以上60℃以下である特許請求の
範囲第1項記載の方法。 5 再生セルロースが鋼アンモニアレーシヨン、ビスコ
ースレーヨンまたはセロファンである特許請求の範囲第
1項記載の方法。 6 再生セルロース誘導体が酢酸セルロースである特許
請求の範囲第1項記載の方法。[Scope of Claims] 1. A heparin derivative obtained by bonding glycidyl acrylate or glycidyl methacrylate to heparin, one or more polymerizable vinyl monomers, and regenerated cellulose or its derivative are combined in water in the presence of a polymerization initiator. A method for imparting anticoagulant properties to regenerated cellulose, which comprises reacting in a solvent. 2 Claim 1 in which the polymerization initiator is hydrogen peroxide-Fe^2^+ type or ceric ammonium nitrate
The method described in section. 3. The method according to claim 1, wherein the aqueous solvent is water. 4. The method according to claim 1, wherein the reaction temperature is above the freezing point and below 60°C. 5. The method according to claim 1, wherein the regenerated cellulose is steel ammonia rayon, viscose rayon, or cellophane. 6. The method according to claim 1, wherein the regenerated cellulose derivative is cellulose acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56046287A JPS5941656B2 (en) | 1981-03-31 | 1981-03-31 | Method for imparting anticoagulant properties to regenerated cellulose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56046287A JPS5941656B2 (en) | 1981-03-31 | 1981-03-31 | Method for imparting anticoagulant properties to regenerated cellulose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57162702A JPS57162702A (en) | 1982-10-06 |
| JPS5941656B2 true JPS5941656B2 (en) | 1984-10-08 |
Family
ID=12742993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56046287A Expired JPS5941656B2 (en) | 1981-03-31 | 1981-03-31 | Method for imparting anticoagulant properties to regenerated cellulose |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5941656B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62148773U (en) * | 1986-03-12 | 1987-09-19 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3341113A1 (en) * | 1983-11-12 | 1985-05-23 | Akzo Gmbh, 5600 Wuppertal | DIALYSIS MEMBRANE WITH IMPROVED TOLERABILITY |
| DE3566954D1 (en) * | 1984-03-20 | 1989-02-02 | Akzo Gmbh | Cellulose dialysis membrane with improved biocompatibility |
| DE3410133A1 (en) * | 1984-03-20 | 1985-10-03 | Akzo Gmbh, 5600 Wuppertal | Dialysis membrane made of cellulose with improved biocompatibility |
| US4840626A (en) * | 1986-09-29 | 1989-06-20 | Johnson & Johnson Patient Care, Inc. | Heparin-containing adhesion prevention barrier and process |
| DE3814326A1 (en) * | 1988-04-28 | 1989-11-09 | Akzo Gmbh | METHOD FOR MODIFYING CELLULOSIC DIALYSIS MEMBRANES FOR IMPROVING BIOCOMPATIBILITY AND DEVICE FOR IMPLEMENTING THE METHOD |
| DE3826468A1 (en) * | 1988-08-04 | 1990-02-15 | Akzo Gmbh | DIALYSIS MEMBRANE FOR HAEMODIALYSIS FROM REGENERATED, MODIFIED CELLULOSE |
| FR2715934B1 (en) * | 1994-02-09 | 1996-05-15 | Serbio | Antithrombogenic glycosaminoglycan polymer material for coating a wall in contact with blood, method of preparation and use. |
-
1981
- 1981-03-31 JP JP56046287A patent/JPS5941656B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62148773U (en) * | 1986-03-12 | 1987-09-19 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57162702A (en) | 1982-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4329383A (en) | Non-thrombogenic material comprising substrate which has been reacted with heparin | |
| JP3974653B2 (en) | Polymerizable modification of polyamide | |
| EP0407580A1 (en) | Medical material and process for their production | |
| US4415490A (en) | Non-thrombogenic material | |
| US20060264355A1 (en) | Separating material | |
| CN113372494B (en) | Anticoagulant polymer coating material and preparation method thereof | |
| JPS5941656B2 (en) | Method for imparting anticoagulant properties to regenerated cellulose | |
| WO2024245021A1 (en) | Amino-containing polymer, and preparation method therefor and use thereof | |
| EP0580871B1 (en) | Water-soluble cellulose derivative and biocompatible material | |
| JP2000279512A (en) | Medical material and manufacturing method | |
| EP1518870B1 (en) | Separating material | |
| JP2000513394A (en) | Polymerizable derivatives of polyamide | |
| JPH07184990A (en) | Medical polymer materials and medical materials | |
| JP3242675B2 (en) | Dialysis membrane for hemodialysis | |
| JP2008194363A (en) | Antithrombogenic coating agent and medical device | |
| JPS5941647B2 (en) | Method for producing anticoagulant regenerated cellulose | |
| JPH07503A (en) | Composite material which is compatible with blood | |
| JPS5932145B2 (en) | Method for imparting anticoagulant properties to acrylonitrile polymers | |
| JP4033514B2 (en) | Soluble cellulose derivatives and uses | |
| JPS5915326B2 (en) | Method for producing anti-blood coagulant acrylonitrile polymer | |
| JPS5811224B2 (en) | Method for producing anti-blood coagulant polymer material | |
| US4252645A (en) | Biocompatible cellulose triacetate fibres for the purification of blood | |
| JP2904286B2 (en) | Dialysis membrane for hemodialysis | |
| JPS5919562B2 (en) | Method for producing heparin derivatives | |
| JPS5915121B2 (en) | Manufacturing method for medical polymer materials |